Translations:SGLT2 inhibitor/23/en
Jump to navigation
Jump to search
| Name of drug | Bioavailability | Protein binding | tmax (hours) | t1/2 (hours) | Cmax | SGLT2 selectivity over SGLT1 |
|---|---|---|---|---|---|---|
| Canagliflozin | 65% (300 mg dose) | 99% | 1–2 | 10.6 (100 mg dose); 13.1 (300 mg dose) | 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) | 250 fold |
| Dapagliflozin | 78% | 91% | 1–1.5 | 12.9 | 79.6 ng/mL (5 mg dose); 165.0 ng/mL (10 mg dose) | 1200 fold |
| Empagliflozin | 90–97% (mice); 89% (dogs); 31% (rats) | 86.20% | 1.5 | 13.2 (10 mg dose); 13.3h (25 mg dose) | 259nmol/L (10 mg dose); 687nmol/L (25 mg dose) | 2500 fold |
| Ertugliflozin | 70-90% | 95% | 0.5-1.5 | 11-17 | 268 ng/mL (15 mg dose) | 2000 fold |
| Ipragliflozin (50 mg) | 90% | 96.30% | 1 | 15–16 (50 mg dose) | 975 ng/mL | 360 fold |
| Luseogliflozin | 35.3% (male rats); 58.2% (female rats); 92.7% (male dogs) | 96.0–96.3% | 0.625±0.354 | 9.24±0.928 | 119±27.0 ng/mL | 1650 fold |